Evaluate Vantage Homepage
Xylocor sees enough to press on with angina gene therapy
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
Medtech
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Company Events
Go or no go? Overcoming delays
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
Immuno-oncology goes subcutaneous
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
The first big test for the son of Enhertu
Readout of Tropion-Lung01, testing the most advanced indication for datopotamab, could lead to a first-half US filing.
Interviews
Astrazeneca gets personal
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
Anthos doubles down on its novel blood thinner
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
Rocket is bringing lenti back
The gene therapy player survived 2022 relatively unscathed, but big tests remain.